SCHEMBL785032

SCHEMBL785032

CN(C(=O)c1ccc2c(c1)C(NC(=O)NCc1ccc(Cl)cc1Cl)CCC2)C1CCN(c2ccncc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
F10 P00742 19/20 0.41
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL785878 0.92 CTSS (0.40) F10LMNASMN1; SMN2
SCHEMBL785135 0.88 POLB (0.39) F10SMN1; SMN2
SCHEMBL785701 0.88 TAS1R3 (0.41) F10LMNA
SCHEMBL784571 0.87 TRPV1 (0.41) F10
SCHEMBL784712 0.86 EPHX2 (0.44) F10LMNASMN1; SMN2
SCHEMBL785726 0.86 TAS1R3 (0.41) F10LMNASMN1; SMN2
SCHEMBL785926 0.85 TRPV1 (0.42) F10LMNA
SCHEMBL785033 0.85 F10 (0.41) F10LMNASMN1; SMN2
SCHEMBL785738 0.85 ALDH1A1 (0.45) F10LMNA
SCHEMBL785666 0.84 TRPV1 (0.44) F10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US claimed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US claimed
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071461-A1 Substituted Benzamide Compounds BDKRB1, BDKRB2, HRH2 F10 524/4885LMNA 1463/4885SMN1; SMN2 2971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.